Navion Neurosciences Closes $10.8M Seed Financing to Advance Precision Sodium-Channel Medicines for Epilepsy and Neuropathic Pain
核心洞察
Navion Neurosciences (搜索) closed a $10.8 million first seed tranche led by the Angelini Lumira Biosciences Fund (搜索) to advance precision sodium-channel therapeutics for genetic epilepsy (搜索) and chronic neuropathic pain (搜索).
Proceeds will fund the company's preclinical lead programs and further development of its AI-enabled NaViGATion platform, which integrates AI chemistry, structural biology and ion-channel expertise.
The company aims to improve the therapeutic window of sodium-channel modulation, a limitation that has historically constrained broad-acting agents in epilepsy and pain.
Navion Neurosciences (搜索), Inc. announced the $10.8 million first closing of a Seed financing round to advance next-generation, precision sodium-channel therapeutics for genetic epilepsy (搜索) and chronic neuropathic pain (搜索). The Angelini Lumira Biosciences Fund (搜索) led the round, with participation from 3B Future Health Fund (搜索), UVA LVG Seed Fund (搜索), Virginia Innovation Partnership Corporation (搜索), VTC Innovation Fund (搜索), and Navion management.
The Charlottesville, Virginia-based company is developing therapies designed to address pathological neuronal hyperexcitability, described as a key driver of uncontrolled seizures and chronic pain. Both lead programs — in genetic epilepsy (搜索) and chronic neuropathic pain (搜索) — remain at the preclinical stage, and the seed capital is intended to generate the data necessary to advance them toward clinical development.
Targeting the Therapeutic Window Problem
Navion's central scientific premise is that existing treatments for these conditions are limited by the poor therapeutic window associated with broad sodium-channel modulation. The company said its integrated discovery approach is designed to achieve more precise modulation of disease-relevant sodium-channel activity, with the aim of dramatically improving the therapeutic window associated with traditional approaches that broadly modulate this biological target — a limitation that has historically constrained the clinical utility of the drug class in both epilepsy and pain.
"Human genetics and advances in sodium-channel pharmacology are creating an opportunity to design much more precise medicines for diseases driven by pathological neuronal firing," said Andrew J. Krouse, Founder and Chief Executive Officer of Navion Neurosciences (搜索). "This financing enables us to advance differentiated programs built around compelling NaV (搜索) biology while continuing to expand a discovery platform capable of generating multiple new medicines. We are building on our team's deep knowledge and expertise in ion-channel science and drug development to develop better treatments for patients living with uncontrolled seizures and chronic pain."
NaViGATion Platform and AI-Enabled Discovery
Proceeds from the financing will support the lead programs as well as continued development of the company's NaViGATion platform, which integrates AI-enabled chemistry, structural biology, human disease biology, and deep ion-channel expertise to discover and optimize differentiated sodium-channel medicines.
Investors pointed to the combination of disease-biology insight, focused pharmacology, and computational tools as the basis for their participation. "Navion combines compelling insights into disease biology with a focused approach to sodium-channel pharmacology and a team with demonstrated experience in the ion-channel field," said Gerry Brunk, Managing Partner at Lumira Ventures (搜索). "Harnessing frontier-level AI tools has rapidly enabled the company to unlock some profound new insights for drug discovery in this field. We believe Navion is well positioned to develop important new medicines for patients with severe neurological diseases and to establish a broader precision sodium-channel discovery platform."
Ion-Channel Heritage and Team
Navion is led by a management and scientific team with decades of expertise in neuroscience, medicinal chemistry, ion-channel biology, and drug development. Members of the leadership team previously built Cavion (搜索), a neurology-focused ion-channel company acquired by Jazz Pharmaceuticals in 2019. Timothy L. Macdonald, whose affiliations span the University of Virginia and Cavion, is among the scientific contributors linked to the company's ion-channel heritage.
Navion is headquartered at the Commonwealth Bio Accelerator in Charlottesville, Virginia.